Open Positions Thank you for your interest! As a growing Biotechnology Startup, we are always looking for new team members. Whether you’re interested in business or have something innovative and unique to bring to the table, we’d love to see if you’re a good fit for Terasom Ltd. Currently, we do not have any open positions. However, you can send us your CV for future opportunities. Get in Touch

Terasom Ltd. is a privately held biopharmaceutical start-up, focused on developing new anti-cancer therapies targeting the tumor microenvironment. About Us Terasom is an innovative, cutting-edge biomedical startup, founded in September 2019, in Prague, Czech Republic. Our main focus is on developing novel exosome-based early lung cancer diagnostic and cancer therapy. Did you know... 2 in 3 lung cancer patients are diagnosed at a late metastastic stage, dwindling 5-year survival rates from 50% to 10%. This statistic is driven by the current high-cost, time-consuming diagnostic methods and the lack of specific lung cancer symptoms. As a consequence, only a small proportion of individuals with symptoms are diagnosed with lung cancer; therefore, widespread screening for lung cancer has not yet been adopted. Nearly 1 in 5 cancer-related deaths is a result of lung cancer, with over 1.8 million deaths per year. This is over double the deaths caused by bowel cancer, the next most deadly cancer. In 2022, over 2.4 million people were diagnosed with lung cancer across the globe. Our Mission At Terasom, we aim to provide an "All in One" platform to cover the 3 key pillars: "diagnose", "treat" and "regenerate", providing complex support for a patient's entire disease journey. Exosomes are tiny bioactive nanostructures containing thousands of proteins, lipids and nucleic acids. Their double bilayer membrane protects them from enzymatic degradation, thus giving them a longer lifespan than other floating biomolecules in the human body, and allowing them to cross over any physiogical barriers. These unique characteristics make them ideal for diagnostic, therapeutic and drug delivery purposes. Click on the links below to find out more about each stage of our All-in-One platform! Diagnose Diagnostics Our novel set of specific lung cancer biomarkers, combined with our rapid detection technology uses a liquid biopsy, to enable the diagnosis of early or metastatic stages of lung cancer within only 15 minutes! View More Treat Immunotherapy Vaccine Using the unique features of our bioengineered exosomes to overcome any physiological barriers, we have developed a new immunotherapy vaccine specifically for solid tumours, aiming to help patients recover from any stage of cancer. View More Regenerate Regenarative medicine We are developing a new regenerative medicine, using exosomes, to revitalise the deteriorated tissue within the patient’s damaged lungs and allow them to catch their breath. View More Our Core Beliefs We draw our values from Stoic philosophy, which emphasizes: Self Awareness Rationality Moral Integrity These principles serve as our Northern Star, helping us remain grounded, resilient, and ethically consistent in a complex and evolving industry frequently subject to disruption and uncertainty. "What disturbs men's minds is not events but their judgements on events." - Epictetus, Enchiridion The principles are rooted in a commitment to the common good, acting with fairness and treating others justly. These values are not merely aspirational, but rather practical and actionable standards that inform and direct how we work, interact, and grow together.

Research & Developement At Terasom, we conduct innovative, complex research to help overcome cancer. Our research team uses an interdisciplinary approach, including bioinformatics, proteomics, three-dimensional biological testing models, and state-of-the-art techniques to develop novel methods to assist those with the terrible disease. We have initiated and grown three projects, which support our company’s vision, based on our “all-in-one” cancer support system. Diagnose Current lung cancer diagnostics rely on imaging and invasive procedures, which are both costly and time-consuming. Therefore, there is a strict eligibility criterion where only the highest-risk individuals are screened. As a result of the long wait times and lack of mass screening, many cases progress to metastasis before diagnosis, minimising survival rates. Our detection method will enable all high-risk patients to be screened by providing a point-of-care early detection system. New Biomarkers Our detection system starts with five new biomarkers, found on the surface of exosomes. These exosomes can be extracted from a simple liquid biopsy from blood, saliva or urine. Three of these five biomarkers are able to indicate early lung cancer stages. IVD diagnostic unit Our diagnostic unit consists of two parts: our electric biomarker detection device and our novel EV isolator. The entire detection process takes no more than 20 minutes, so no one has to wait at home for test results nervously. This detection platform can also be used for the early detection of prostate cancer and has prospective applications in the early diagnosis of other conditions such as breast cancer, Alzheimer's disease, Parkinson's disease and various cardiovascular diseases. Treat Immunotherapy Vaccine We have developed an exosome-based vaccine that functions both as an immunotherapy for lung cancer patients and as a prophylactic vaccine for at-risk individuals. By engineering exosomes to display cancer-specific antigens on their surface, we intend to stimulate an adaptive immune response that eliminates existing cancer cells to prevent any possible future occurrence. This approach leverages three distinct tumour-associated antigens (TAAs) that are surface-loaded onto isolated immune cell-derived exosomes. This method surpasses others due to its ability to kill cancerous stem cells, which is the cause of ~80% of recurrence rates within cancer patients. The treatment also causes a 'tumour softening' effect, allowing the immune system to better reach cancer cells compared to other therapies. Regenerate Regenerative Medicine Exosomes' main responsibility within the body is to transmit signals between cells. We have found a method to re-engineer isolated human stem cell exosomes to target damaged tissue by stimulating elastin biogenesis. Our Patents New Biomarkers EV isolation device Immunotherapy Vaccine

Leadership Founder & Co-Owner Dr. Daniela Pankova Dr. Daniela Pankova established Terasom Ltd. In 2019 and currently serves as President and Chief Executive Officer for the company. She has spent 18 years in cancer research field, focused on tumor microenvironment and metastatic spreading. After receiving her doctoral degree at Charles Univerity, she served as a postdoctoral fellow at MD Anderson Cancer Center in Houston, TX, USA and at Oxford University in England. Dr. Pankova was involved in numerous research interdisciplinary projects and has been extensively published in the cancer research field. Investor & Co-Owner Jonathan Adrian Jackson A few years after completing his degree in Business Management in London, Jonathan Jackson set up his own company to develop commercial real estate in Central Europe. Over the last 25 years, he has currently under development and developed more than 15,000,000 sqft of space. Since selling a portfolio of completed assets in early 2007 in one of the largest deals in Central Europe and Africa, Mr Jackson has diversified and invested over $15M in different business sectors, in the USA, Europe and Africa with great success. Scientific Advisor Jonathan Meigs Kurie, MD Professor Jonathan Kurie holds an MD degree from Chapel Hill Medical school in North Carolina and has more than 40 years of experience in lung oncology and lung cancer research at MD Anderson Cancer center, Houston, USA. In the past, Professor Jonathan Kurie led a few clinical trials at MD Anderson Cancer Center, focused on the effects of dietary supplements on lung cancer development. Besides of his very successful clinical career and cancer research publication activity in high impact factor international journals, Professor Kurie is successfully awarded by various prestigious grants over his entire clinical and scientific career. Business Advisor Mr. Nicholas Adams Mr. Nicholas Adams holds law degree from College of Law in London and over the past 35 years he has been working as chief business officer at various anti-cancer drug development companies, including company focused on application of exosomes in neurodegenerative diseases. Mr. Adams was involved in many successful deals from which the most outstanding was to out-license the product for $161M.

Terasom Ltd. is a privately held biopharmaceutical start-up, focused on developing new anti-cancer therapies targeting the tumor microenvironment. Turning the tides against lung cancer "Lung cancer is the leading cause of cancer-related deaths worldwide" - International Agency for Research on Cancer, 2023 What we do? At Terasom, we harness and bioengineer exosomes—naturally occurring extracellular vesicles secreted by all human cells—to confront lung cancer across its entire clinical spectrum. Whether a patient is navigating stage IV disease, struggling with post-surgery symptoms, or simply in the high-risk category, our exosome-based approach is designed to intervene, support, and prevent lung cancer, to ensure everyone can breathe easy. Read More How we do this? With the power of exosomes, we have created: A novel platform for rapid early-stage lung cancer diagnostics An immunotherapy vaccine for solid tumours An exosome-based drug that can induce the regeneration of elastin Read More

Contact Us Terasom ltd. (6.th floor), V Jame 699/1, Prague 1, 11000, Czech Republic Luke.Allen@terasom.org +420 228 808 360